 %IdPhases!MetadataAInternalMetadataGroups!Sections+OriginalId#MeasuresGSupplementalFilesÚ´±ë IdNameTime$BATreatment PeriodÛøëÅ«ø $	'HAFollow-up PeriodÛøëÅ«øuDesignsTypes0Created"AbstractAuthors>CorporateAuthorCountry)CustomData2DatabaseTypeDOI.FullTextURLISSN2JournalTitle'MedlineIDFParentChildStatus#ParentID>PublicationDate?PublicationYearPubType;ReferenceStudySource6TaStudyDesignTitle3TrialOutcome?FramedQuestionsSources'Digitized:CollectionTypem0123456789
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26Randomized Controlled Triallhd`\XTTherapyÚ™¶π«øq2017-02-10T14:50:02.4194672Z·°ïBACKGROUND:  Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis.  OBJECTIVE:  To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials.  METHODS:  Patients who were treatment naive (Comparison of Alemtuzumab and Rebif(¬Æ) Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 ¬µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36).  RESULTS:  Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS.  CONCLUSION:  Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.ƒΩArroyo Gonz√°lez R|Kita M|Crayton H|Havrdova E|Margolin DH|Lake SL|Giovannoni G|}CARE-MS I and II Investigators|EnglandMEDLINEa10.1177/1352458516677589¬©http://dx.doi.org/10.1177/1352458516677589U1477-0970(Electronic)√ïMultiple sclerosis (Houndmills, Basingstoke, England)Ûü†ï√î Ú©∑ï-2016 Nov 24·æÅ=Journal ArticleÚ´±ëaMult Scler. 2016 Nov 24;RCT ùAlemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. [CARE-MS I]IPartial Collection!VOriginal Text Task IdNOriginal FR Task Id¬ñOriginal Error Report - High Priority¬íOriginal Error Report - Low PriorityUpdated/HasFullText*ImportType:EncryptedRefId324390‡°µ<h3><B>Source: <U>Text</U></B></h3><B>Type: <U>Results</U></B><br><br>Attribute <B>"FAMS, Family AND Social Well-Being Score"</B> in Group <B>"Alemtuzuamb 12 mg qd 2yr"</B> contains unparseable/blank Field Value data. Fix the Field Type, data, and/or set to 'Not Reported' if meant to be blank.<br style='mso-data-placement:same-cell;' >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Mean Value: 0.+5<br style='mso-data-placement:same-cell;' >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: SE Value: 0.29<br style='mso-data-placement:same-cell;' ><br>‚íô<h3><B>Source: <U>Text</U></B></h3><B>Type: <U>Study</U></B><br><br><font color='green'>This study contains a blank Study Level Source that will not be imported.</font><br style='mso-data-placement:same-cell;' ><br><B>Type: <U>Results</U></B><br><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "EDSS" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "FAMS, Total Score" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "SF-36, MCS Score" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "SF-36, PCS Score" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "EQ-5D" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br><font color='green'>This study contains a Result with an Interval where the Characteristic checking logic (GitHub Task #1055) overrode what was originally sent over from Extract. Attribute "EQ-VAS" is Outcome?</font> <B>Initial Value: True, Converted Value: False, Interval: Baseline (Maximum)</B><br style='mso-data-placement:same-cell;' ><br>q2017-08-31T07:46:19.2181567ZExtractAB%2fx813aOHqs%3dƒàRefId2OriginalName+IsSubGroup;IsIntervention$	.+q1879828_ext-data-31163145256ATotal Populationƒò7Interventions$~ ƒúName+Treatments$	KVÚìà±»å 	ƒ§Phase$	9nBq1879828_ext-data-81221416389aAlemtuzuamb 12 mg qd 2yr$	LX $3ÚØ¥â≈π $em1879828_ext-data-8122133238¬ÅInterferon-beta 1a 44 ug tiw 2yr!!Outcomes=Characteristics%Inclusion%ExclusionIUncollectedResults)StudyLevel)GroupLevelEInterventionLevelRows√≥1≈å0Cells≈Ñ'IsOutcome+IsPositive"Category1PDFLocations*Definition+TableNamesTypePopType$!67021818Ú™ø•«ø ≈∞GroupNPopNameStatus$	P)	.+‡£ç)Randomized	NR $PxV	LXÀ≠ ∆ÄNumber$	@Sƒù~◊°ÚÄéç»Ä5Adverse EventExtras: Appendices, Supplements	NR$USupplementary Table 2-Participant-Participant$!67021821Ú™ø±«ø $R1V‡£ç $	@JÀ≠ $	sm”Ö◊°ÚÄéç»Ä$USupplementary Table 25∆àl<RowType∆Ä840(Method Unit$!68701316Úêì° $	sP‡¢π)Population ∆îSE$ $	0'0.0460.017 µ1Participants $	a70.0390.013÷°ChangeÚÄéç»Ä5Scales/Scores€µEuropean Quality of Life-5 Dimensions (EQ-5D) is a generic, standardized, and validated instrument that provides a simple, descriptive profile, and a single index value comprising five dimensions of health: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Health states are converted to utility scores using country-specific value sets describing the preference of the population for one health state over another.Grab-itMeanunits$!68701317Úêì° $	:W‡¢π $	d+0.0610.017 © $	HI0.0640.013÷≠ÚÄëô»Ä
$!68701318Úêì° $Qau‡¢π $	A]0.0480.015ÀÖ $	IA0.0750.012◊ÅÚÄëï»Ä
$!68701319Úêì° $	1'‡¢π $	d[0.0370.016Àï $	']0.0470.012÷πÚÄêç»Ä
$!68741307Ú†í© $9S.‡£ç $	SF3.51.4 µ $	y25.10.94÷©ÚÄéç»ÄÕçEuropean-Quality of Life-5 Dimensions, Visual Analog Scale (EQ-VAS) captures patients‚Äô self-rating of current health status using a visual analog scale ranging from 0 to 100 (higher scores represent better QoL).	mm
$!68741308Ú†í© $	9H‡£ç $(tw5.61.3 ≠ $xDf6.40.94÷µÚÄëô»Ä
$!68741309Ú†í© $	!Y‡£ç $	~@4.21.1Àâ $	Ui7.20.88÷ΩÚÄëï»Ä
$!68741310Ú†í© $	](‡£ç $	l=3.61.1Àô $	G.0.88÷ΩÚÄêç»Ä=∆ò|L∆êHD@8<40,$!68700327Ú™πµ«ø $987‡£ç $	@B1.10.34À≠ 
$	2F1.30.3◊°ÚÄéç»Ä…ôFunctional Assessment of Multiple Sclerosis (FAMS) is a validated, patient-reported, MS-specific, multicomponent, quality of life (QoL) questionnaire.$YSupplementary Figure 1$!68700328Ú™πµ«ø $	Lw‡£ç 
$	$+1.30.34À≠ 
$uED1.60.3◊°ÚÄëô»Ä$YSupplementary Figure 1$!68700329Ú™πµ«ø $	54‡£ç 
$	871.40.34À≠ 
$	e41.60.3◊°ÚÄëï»Ä$YSupplementary Figure 1$!68700330Ú™πµ«ø $	RN‡£ç 
$	QL0.3À≠ 
$	Yu1.60.3◊°ÚÄêç»Ä$YSupplementary Figure 1$!68700331Ú™∫ô«ø $	1E‡£ç 
$	ZT0.320.33À≠ÚÄéç»Ä$YSupplementary Figure 1$!68700333Ú™∫ô«ø $	V#‡£ç 
$	QU0.70.31À≠ 
$	y)0.810.28◊°ÚÄëï»Ä$YSupplementary Figure 1$!68700334Ú™∫ô«ø $	eD‡£ç 
$	'70.610.28À≠ 
$	Z.0.840.31◊°ÚÄêç»Ä$YSupplementary Figure 1$!68701183Ú™∫ô«ø $	iU‡£ç 
$Bil0.160.34À≠ 
$	]w0.70.32◊°ÚÄëô»Ä$YSupplementary Figure 1$!68700323Ú™πë«ø $	i9‡£ç 
$	YZ1.30.41À≠ 
$	Lo	0.34◊°ÚÄéç»Ä$YSupplementary Figure 1$!68700324Ú™πë«ø $	CZ‡£ç 
$	[j1.10.42À≠ 
$	BI	0.31◊°ÚÄëô»Ä$YSupplementary Figure 1$!68700325Ú™πë«ø $	IT‡£ç 
$	(j1.20.34À≠ 
$	PE1.80.34◊°ÚÄëï»Ä$YSupplementary Figure 1$!68700326Ú™πë«ø $	fR‡£ç 
$	'+1.20.29À≠ 
$	'n1.80.28◊°ÚÄêç»Ä$YSupplementary Figure 1$!68700311Ú™∑°«ø $	EI‡£ç 
$	D10.840.45À≠ 
$	0x1.70.34◊°ÚÄéç»Ä$YSupplementary Figure 1$!68700312Ú™∑°«ø $	Wl‡£ç 
$	!z1.10.4À≠ 
$	Dh2.10.29◊°ÚÄëô»Ä$YSupplementary Figure 1$!68700313Ú™∑°«ø $D‡£ç 
$	0V1.20.43À≠ 
$	D*2.10.31◊°ÚÄëï»Ä$YSupplementary Figure 1$!68700314Ú™∑°«ø $	@D‡£ç 
$	*d0.910.36À≠ 
$	M@1.70.33◊°ÚÄêç»Ä$YSupplementary Figure 1$!68700315Ú™∏Ö«ø $	V*‡£ç 
$	vD0.340.23À≠ 
$	J20.850.31◊°ÚÄéç»Ä$YSupplementary Figure 1$!68700316Ú™∏Ö«ø $	yx‡£ç 
$	Yf0.640.39À≠ 
$	Ni1.50.31◊°ÚÄëô»Ä$YSupplementary Figure 1$!68700317Ú™∏Ö«ø $	6(‡£ç 
$	790.430.38À≠ 
$	KY1.60.31◊°ÚÄëï»Ä$YSupplementary Figure 1$!68700318Ú™∏Ö«ø $	(S‡£ç 
$	vy0.340.39À≠ 
$	rb1.40.31◊°ÚÄêç»Ä$YSupplementary Figure 1$!68701182Ú™∏Ω«ø $	Ju‡£ç 
$	JC0.57À≠ 
$	nD2.30.41◊°ÚÄëô»Ä$YSupplementary Figure 1$!68700319Ú™∏©«ø $	)T‡£ç 
$	+20.810.61À≠ 
$	2j1.90.44◊°ÚÄéç»Ä$YSupplementary Figure 1$!68700321Ú™∏©«ø $	Y~‡£ç 
$	!.1.20.57À≠ 
$9wF2.60.44◊°ÚÄëï»Ä$YSupplementary Figure 1$!68700322Ú™∏©«ø $	!A‡£ç 
$	&k1.20.48À≠ 
$	sv1.80.44◊°ÚÄêç»Ä$YSupplementary Figure 1$!68701178Ú™Æ•«ø $	8A‡°ï 
$	:D3.561.94 © 
$	hW7.691.56÷≠ÚÄéç»Ä€ÖFunctional Assessment of Multiple Sclerosis (FAMS) is a validated, patient-reported, MS-specific, multicomponent, quality of life (QoL) questionnaire. || Total score is the sum of 44 scored items from six clinically relevant scales: mobility, symptoms, emotional well-being, general contentment, thinking and fatigue, and family/social well-being. Total scores range from 0 to 176, with higher scores representing better functioning.$!68701179Ú™Æ•«ø $	el‡°ï 
$	xK3.941.81 ô 
$	K29.131.44÷ΩÚÄëô»Ä$!68701180Ú™Æ•«ø $	GF‡¢Ö 
$	Or5.131.87ÀÅ 
$	IC9.51.44◊ÖÚÄëï»Ä$!68701181Ú™Æ•«ø $	XR‡£Å 
$	5B4.131.69Àç 
$	Dm!1.37◊çÚÄêç»Ä9∆ò|L∆êHD@8<+TableNames0,$!68700353Ú∞æ± $	qh‡£ç ∆úSD,($$E~F-0.910.59À≠ $	vf1.79.5◊°ÚÄëï»Ä–çShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL).$USupplementary Table 1$!68700354Ú∞æ±  $	Jf‡£ç $	#.-0.810.89À≠ $	hG0.210.23◊°ÚÄéç»Ä$USupplementary Table 1
$!68700355Ú∞øâ "$	yF‡£ç $	6=1.28.49À≠ $	B:2.68.34◊°ÚÄëï»Ä$USupplementary Table 1
$!68700356Ú∞øâ "$	Kh‡£ç $WIf2.28.94À≠ $	j#	9.36◊°ÚÄéç»Ä$USupplementary Table 1$!68701184Ú™Æ±«ø "$	CA‡°± $	4G3.10.73 µ $	GZ2.90.58÷ΩÚÄëï»Ä—ΩShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Mental Component Summary$!68701313Ú™Æ±«ø "$	v#‡°ï $+f)2.70.82 © $h&D2.70.63÷≠ÚÄéç»Ä‹≠Short-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Mental Component Summary (MCS); an aggregate score comprising the eight scales emphasizing the mental health, role-emotional, social functioning, and vitality [i.e. energy level/tiredness] scales.)∆†¬ÑT∆òPLH@84$!67021755Ú™ª©«ø $$	j2‡£ç ∆†Percent0,($	z235.2À≠ $	i032.6◊°ÚÄéç»Ä‡∞ôShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Mental Component Summary (MCS); an aggregate score comprising the eight scales emphasizing the mental health, role-emotional, social functioning, and vitality [i.e. energy level/tiredness] scales. Clinically meaningful worsening and improvement on the summary measures were defined as >=5-point decrease and increase from baseline norm-based scores, respectively. The 5-point cutoff was based on half a SD, which represents a minimally important difference, and has been used in other studies of MS-related QoL.$!68700341Úòàµ ($	X&‡£ç $	qY1.310.32À≠ $	X51.99.27◊°ÚÄëï»Ä $USupplementary Table 1$!68700342Úòàµ *$	dZ‡£ç $	1(1.89.48À≠ $	n91.79.83◊°ÚÄéç»Ä"$USupplementary Table 1$!68701314Ú™ÆΩ«ø *$	W[‡°ï $	vP1.10.58 µ $	f33.30.49÷ΩÚÄëï»Ä⁄çShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Physical Component Summary (PCS); an aggregate of the eight scales emphasizing the physical function, role-physical, bodily pain, and general health scales.$!68701315Ú™ÆΩ«ø *$	DM‡¢π $	Nb1.50.37 © $	Y'2.40.52÷≠ÚÄéç»Ä$!67021752Ú™ªù«ø *$	//‡£ç $	6G23.5À≠ $	1u30.5◊°ÚÄéç»Ä‡≠πShort-Form Health Survery It comprises 36 items organized into eight scales, typically combined into two summary measures: the mental component summary (MCS) and the physical component summary (PCS).Higher global scores represent better quality of life (QoL). || Physical Component Summary (PCS); an aggregate of the eight scales emphasizing the physical function, role-physical, bodily pain, and general health scales. Clinically meaningful worsening and improvement on the summary measures were defined as >=5-point decrease and increase from baseline norm-based scores, respectively. The 5-point cutoff was based on half a SD, which represents a minimally important difference, and has been used in other studies of MS-related QoL.$!68700349ÚÖõ±t *$	z)‡£ç $	f$0.37.69À≠ $	W:1.76.86◊°ÚÄëï»Ä"$USupplementary Table 1$!68700350ÚÖõ±t *$	E@‡£ç $	fd0.69.27À≠ $	7c1.37.99◊°ÚÄéç»Ä"$USupplementary Table 1$!68700343Ûåäù≈¥ *$	Oe‡£ç $	PD2.311.32À≠ $	cC1.49.95◊°ÚÄëï»Ä"$USupplementary Table 1$!68700344Ûåäù≈¥ *$	o3‡£ç $3tg1.412.76À≠ $A)T11.11◊°ÚÄéç»Ä"$USupplementary Table 1$!68700351ÚÖõΩt *$	GQ‡£ç $	pX1.79.89À≠ $FRv3.48.87◊°ÚÄëï»Ä"$USupplementary Table 1$!68700352ÚÖõΩt *$	BG‡£ç $	yz	10.44À≠ $5M23.29.42◊°ÚÄéç»Ä"$USupplementary Table 1$!68700345Ú±Åâ *$	kv‡£ç $	kI1.910.41À≠ $	zJ2.48.69◊°ÚÄëï»Ä"$USupplementary Table 1$!68700346Ú±Åâ *$	OK‡£ç $	=p1.310.84À≠ $vla2.410.36◊°ÚÄéç»Ä"$USupplementary Table 1$!68700347ÚòâÅ *$	s/‡£ç $	E!0.99.73À≠ $	lX2.58.65◊°ÚÄëï»Ä"$USupplementary Table 1$!68700348ÚòâÅ *$	+C‡£ç $	2u1.310.73À≠ $	1Y2.110.01◊°ÚÄéç»Ä"$USupplementary Table 10#)∆§¬àX∆úCIsCharacteristicLD<8$!46444828ÚµÉÅ ,$	cb‡£ç $	w:	0.79À≠ $	Oz	0.81◊°ÛæΩ©«ø¬ÅExpanded Disability Status Scale$!68700357Úêì° .$	C:‡£ç $	(h0.780.19À≠ $	Pn0.770.21◊°ÛæΩ©«ø,$!68739552Ú†í© .$	kd‡£ç $	1j75.9415.89À≠ $	y!75.817.87◊°ÛæΩ©«ø($!68700306Ú™Æ•«ø .$	y(‡£ç $	hy134.227.61À≠ $	C3133.427.65◊°ÛæΩ©«ø -∆®¬å\ ∆†PH@<$!48856398Ú¥∏• 0$v:#‡£ç $	cj	1.32À≠ $	B72.11.36◊°!DurationÛæΩ©«ø=Medical HistorymTime since initial episodes	yr)∆®¬å\∆†TPH@<$!68700305Úçäπ 4$	.V‡£ç $	!G1.80.83À≠ $	]11.80.81◊°ÛæΩ©«ø4$!68700335Ú™Æ±«ø 6$	bm‡£ç $dy]45.411.26À≠ $	4D46.510.95◊°ÛæΩ©«ø$!68700336Ú™ÆΩ«ø 6$	aJ‡£ç $	ma48.38.41À≠ $	N[47.98.62◊°ÛæΩ©«ø<∆®¬å@P$!67021497Ú™´°«ø∆ë1Demographics$!67021494Ú™´ï«ø∆ë$!67021491Ú™´â«ø∆ë$!68701174Úíøï»å∆ë$!68701326Úìàµ»å∆ë$!67021488Û∫ãô∆ë@∆®¬å@($!67021506Ú™¨Ö«øD#!∆®¬å@Stats+TimePointsX>UncollectedType1SubgroupName$!68700298Úíà•»åUUncollectedContinuous)Continuous¬úÚíåΩ»å$!68700299Úíà•»åÚíçÅ»å
$!68701176Úíøù»åÚíåΩ»å
$!68701177Úíøù»åÚíçÅ»å
$!68700295Úíàô»åÚíåΩ»å
$!68700296Úíàô»åÚíçÅ»å
$!68700292Úíàç»åÚíåΩ»å
$!68700293Úíàç»åÚíçÅ»åLC∆∏¬ú`lP$!21514956Ê∞•1Study Design 	∆∏Value$qDrugString$!21514960ê°ï $K	No
$!21523959£π≠ $zUOpen Blinded Endpoint
$!39906888¶îΩ $u-NCT00530348-LookupTable
$!39906893±èÖ $w3∆º¬†pdTP$!21514922•ûπ ∆º<3IsDefaultPop$[‡£çAStudy PopulationInteger«Ä¬§thX$!21514938®çÅ «Ä@HL$cÃô‡£ç$!21514940®çë $a÷µ‡£ç
$!21514942ÚÆ∑•¬Ü «Ä@ HL$s‡£ç«Ä¬§thX$!61885785êüµ $==Journal Article9Study Document$!21519514ê°Ω «Ä-FundingType=InstitutionType$y(ê¢â*·Ñë5Study FundingFunding$!21514966ëØÖ  $	@8œâMultiple Sclerosis, Relapsing-Remitting, Active|>= 2 relapses in prior 2 years|>= 1 relapse in the prior year|18‚Äì50 years of age|Baseline expanded disability status scale (EDSS) score <= 3|Multiple Sclerosis (MS) symptom onset within 5 years|)Study Data
$!21517349£ª≠ "$	NM√ÅPrevious use of disease-modifying therapy (DMT)|
$!61886395ÚÜ∂ï«Å "$.%CARE-MS I5Study Setting«à¬¨|p`8$!21516048®™ù «à$	q$eStudy Phase Randomization%UnitValue!Baseline$!68737533Ú∂ü±»å ($6YesIAll Arms Extractedx«à|`¬¨$!21514940 «àHXPT$*÷µ‡£ç «àH(XPT$	2~œç64.6◊° $F«©65.2À≠ ®çë$!21514938 $)Ãô‡£ç $o»ï35.4◊° $VƒÖ34.8À≠ ®çÅ«à|`\¬¨$!21514922 «àHX$]‡£ç $	h(◊° $@À≠•ûπ$!21514942 $(‡£ç $	:V◊° $	x6À≠ ÚÆ∑•¬Ü$!21517413 «àX$4»≠Patients recevied alemtuzumab 12mg/day intravenous (IV) once daily on 5 consecutive days at baseline and on 3 consecutive days at Month 12. $1≈±Patients received interferon-beta 1a (IFNB-1a) 44 ug subcutaneously (SC) three times weekly.ëÉô«à|`8¬¨$!21514936 «àH,XPT$	'K¬Ö8.03◊° $O33.28.48À≠Ê±•RowsÚ™¶π«ø¬ó !«ådRangesAMTypeL<LeftRight$	2AIAssociationMeasure t<LowLHigh	CI≈Ωd0.078.44=Mean Difference4.25$	hW$	:D «§|&POperatorPValue$	r9PValue<0.05$	hW$	:D$	hW$	:D $	4w0.05$	K2$	xK$	K2$	xK $ERf ≈Ω1.33
8.995.16$	K2$	xK $	1t ≈Ω
0.67
8.164.42$	IC$	Or $eGj0.05$	IC$	Or$	IC$	Or $	'y0.05$	Dm$	5B$	Dm$	5B $	[3 ≈Ω
0.69
6.993.84$	Dm$	5B $	Kg0.05$	M@$	*d$	M@$	*d $	k40.05$	D*$	0V$	D*$	0V $	3'0.05$	Dh$	!z$	Dh$	!z $TE/0.05$	0x$	D1$	0x$	D1 $	i*0.05$	rb$	vy$	rb$	vy $	1D0.05$	KY$	79$	KY$	79 $kmR0.05$	Ni$	Yf$	Ni$	Yf $	VR0.05$	BI$	[j$	BI$	[j «¨¬Ñ7IsSignificant$	Co0.05$	f3$	vP$	f3$	vP !«∞¬à p$AY*=0.14)Odds Ratio1.39$	1u$	6G $	p30.880.97$	i0$	z2 $	x@0.2392$	X5$	qY$	X5$	qY $	JN0.6306$	n9$	1($	n9$	1( $	+]0.4249$	cC$	PD$	cC$	PD $	8*0.8202$A)T$3tg$A)T$3tg $	9u0.2255$	zJ$	kI$	zJ$	kI $	Dz0.085$vla$	=p$vla$	=p $	sl0.0727$	lX$	E!$	lX$	E! $	*n0.8019$	1Y$	2u$	1Y$	2u $	cm0.0036$	W:$	f$$	W:$	f$ $	ta0.2423$	7c$	fd$	7c$	fd $F!/0.0117$FRv$	pX$FRv$	pX $huH0.108$5M2$	yz$5M2$	yz $	yK0.0085$	vf$E~F$	vf$E~F $	i!0.7179$	hG$	#.$	hG$	#. $	Ep0.0317$	B:$	6=$	B:$	6= $	3#0.9619$	j#$WIf$	j#$WIf $	qK0.05$	Ui$	~@$	Ui$	~@ $	uj0.05$	G.$	l=$	G.$	l= 	[ReferencePackageFileId"FileNameÔøΩUSupplement Data 1.pdf ÔøΩUSupplement Data 2.pdf